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Abstract
Aims Neuregulin1-β (NRG1-β) is released from microvascular endothelial cells in response to inflammation with compensa-
tory cardioprotective effects. Circulating NRG1-β is elevated in heart failure (HF) with reduced ejection fraction (HFrEF) but not
studied in HF with preserved EF (HFpEF).
Methods and results Circulating NRG1-β was quantified in 86 stable patients with HFpEF (EF ≥45% and N-terminal pro-brain
natriuretic peptide >300 ng/L), in 86 patients with HFrEF prior to and after left ventricular assist device (LVAD) and/or heart
transplantation (HTx) and in 21 healthy controls. Association between NRG1-β and the composite outcome of all-cause
mortality/HF hospitalization in HFpEF and all-cause mortality/HTx/LVAD implantation in HFrEF with and without ischaemia
assessed as macrovascular coronary artery disease was assessed. In HFpEF, median (25th–75th percentile) NRG1-β was 6.5
(2.1–11.3) ng/mL; in HFrEF, 3.6 (2.1–7.6) ng/mL (P = 0.035); after LVAD, 1.7 (0.9–3.6) ng/mL; after HTx 2.1 (1.4–3.6) ng/mL
(overall P < 0.001); and in controls, 29.0 (23.1–34.3) ng/mL (P = 0.001). In HFrEF, higher NRG1-β was associated with worse
outcomes (hazard ratio per log increase 1.45, 95% confidence interval 1.04–2.03, P = 0.029), regardless of ischaemia. In HFpEF,
the association of NRG1-β with outcomes was modified by ischaemia (log-rank P = 0.020; Pinteraction = 0.553) such that only in
ischaemic patients, higher NRG1-β was related to worse outcomes. In contrast, in patients without ischaemia, higher NRG1-β
trended towards better outcomes (hazard ratio 0.71, 95% confidence interval 0.48–1.05, P = 0.085).
Conclusions Neuregulin1-β was reduced in HFpEF and further reduced in HFrEF. The opposing relationships of NRG1-β with
outcomes in non-ischaemic HFpEF compared with HFrEF and ischaemic HFpEF may indicate compensatory increases of
cardioprotective NRG1-β from microvascular endothelial dysfunction in the former (non-ischaemic HFpEF), but this compen-
satory mechanism is overwhelmed by the presence of ischaemia in the latter (HFrEF and ischaemic HFpEF).
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Introduction
Heart failure (HF) is categorized according to left ventricular
ejection fraction (LVEF) as being reduced (HFrEF) or preserved
(HFpEF), and lately also a mid-range (HFmrEF)1, all common
and associated with poor prognosis. Pharmacological
treatments in HFrEF have decreased morbidity and mortality,
but prognosis remains poor. In HFpEF, often including patients
with HFmrEF, trials have been neutral suggesting different or
heterogeneous underlying pathophysiologies.
In both HFpEF and HFrEF, endothelial dysfunction is as-
sociated with incident HF, disease progression, and adverse
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outcomes,2 but its role may differ. In HFrEF, direct cardio-
myocyte injury is a key trigger, while in HFpEF, co-morbid-
ity-driven endothelial dysfunction plays a dominant role.3
Neuregulin-1 (NRG1) is a membrane bound vasculo-
active peptide and part of the epidermal growth factor
family. It is released by proteolytic cleavage from endothe-
lial cells in the microvasculature in several tissue types, in-
cluding the heart, in response to inflammation,
ischaemic, and oxidative stress.4–6 NRG1 affects
cardiomyocytes by activating tyrosine kinase receptors,
such as ERBB4 and ERBB2, activating downstream signalling
through the phosphatidylinositol 3-kinase and mitogen-
activated protein kinase pathways thereby inhibiting apo-
ptosis and inducing cardiomyocyte proliferation.5,6 NRG1
has at least 31 isoforms with different epidermal growth
factor-like domains, but NRG1-β is the most extensively
studied.
In the HFrEF myocardium, both the ERBB2 and ERBB4
receptors are downregulated, whereas NRG-1 expression
is upregulated,7 and circulating NRG1-β has been
associated with HF severity and mortality.8 In HFpEF,
NRG1-β and its prognostic impact have not been studied.
Furthermore, the implications of NRG1-β may differ de-
pending on the HF aetiology (ischaemic versus non-
ischaemic).8
We aimed to explore circulating NRG1-β, its
prognostic role in HFpEF and HFrEF, and the impact of is-
chaemia in patients with HFrEF, before and after left ven-
tricular assist device (LVAD) therapy, and heart
transplantation (HTx).
Methods
Patients
Patients were recruited between 21 May 2007 and 29 De-
cember 2011 at Karolinska University Hospital, Stockholm,
Sweden. Patients with decompensated HFpEF (n = 86), N-
terminal pro-brain natriuretic peptide (NT-proBNP) >300
ng/L, and LVEF ≥45% were enrolled. Follow-up at the hospital
was performed in stable condition after 4–8 weeks including
blood sampling and echocardiography (regarded as baseline
in the present analysis). Patients with HFrEF (n = 86) referred
for assessment for LVAD or Tx and LVEF <40% were enrolled.
Blood sampling was performed prior to LVAD/HTx (n = 86),
cross-sectionally 1 year after LVAD implantation (n = 26) or
HTx (n = 35).
Healthy individuals (n = 21) with systolic blood pressure <
150 mmHg, body mass index < 35, free from hypertensive
treatment, and known macrovascular coronary artery disease
(CAD) were blood-sampled.
Laboratory analyses
Blood samples were collected in a fasting state in the
morning in ethylenediaminetetraacetic acid tubes and cen-
trifuged, and plasma was aliquoted and stored in 70 °C
until analysis. NRG1-β was assessed with enzyme-linked im-
munosorbent assay RAB0388, Sigma-Aldrich Sweden AB. It
includes antibody pre-coated plate(s) and other compo-
nents needed to perform the assay. This NRG1-β solid-
phase, sandwich enzyme-linked immunosorbent assay
detects the amount of the specific protein bound between
a matched antibody pair. After incubation periods and
wash steps, a substrate solution was added that produces
a measurable signal. The intensity of this signal is propor-
tional to the concentration of target present in the original
specimen. The intensity was measured with a Microplate
Reader (SpectraMax 250, Molecular Devices, USA) at
450 nm.
N-terminal pro-brain natriuretic peptide was analysed by
proBNPII (Roche Diagnostics, Bromma, Sweden). In addition
to insulin-like growth factor (IGF)-1 values with age adjusted
standard deviation scores calculated from the regression of
the IGF-1 concentrations of healthy adult subjects (standard
deviation score = ((10lnIFG-1  observed + 0.00693*age) 
2.581)/0.120) were calculated. Insulin resistance was
assessed according to homeostatic model assessment of insu-
lin resistance calculated as ([glucose*Insulin]/22.5; with glu-
cose in mmol/L and insulin in mU/L) and estimated
glomerular filtration rate to the Modification of Diet in Renal
Disease equation.
Doppler–echocardiography
The echocardiographic assessment was performed on a ViVid
7 echo-platform (GE VingMed, Horten, Norway) and analysed
in a dedicated core centre in Hôpital Pontchaillou-CHU,
Rennes, France. Each examination was interpreted once,
and measurements were performed three times and aver-
aged by an echocardiographist (E. D.) blinded to the specific
clinical history of the patient. Diastolic dysfunction was
assessed as ratio of early transmittal velocity to mitral annu-
lar early velocity (E/e′) >15 and structural heart disease as ei-
ther left atrial volume index (LAVI) calculated as left atrial
volume in millilitres divided by body surface area in m2)
>34 mL/m2 or left ventricular hypertrophy defined as left
ventricular mass index ≥95 g/m2 in women and ≥115 g/m2
in men, respectively.1
Endpoints
Patients with HFpEF were followed until 30 September 2012
when vital status was assessed by telephone contact or by
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the Swedish National Patient Register and Population Regis-
ter. The primary composite endpoint was defined as time to
mortality from any cause or first hospitalization due to HF.
All HF hospitalizations were adjudicated and defined accord-
ing to clinical judgement by the local investigator, and addi-
tionally, centrality was validated to confirm the presence of
HF at hospitalization.
In patients with HFrEF, implantation of LVAD or HTx
was assessed by patient charts in December 2014
and vital status by the Swedish National Patient and Popu-
lation Registers. In such patients, the primary composite
endpoint was death from any cause, implantation of LVAD,
or HTx.
Statistics
Descriptive data in Table 1 is expressed as median and
quartiles (Q1;Q3) or number (%) and compared by the
Wilcoxon rank-sum test and Fisher’s exact test in HFpEF
versus HFrEF and Kruskal–Wallis test and χ2 between
HFrEF, LVAD, and HTx. Difference in NRG1-β concentrations
between HF-groups and controls and NYHA classes was de-
termined by ANOVA and analysis of covariance. Bivariate
correlations with plasma or serum biomarkers and clinical
variables were established by linear and logistic regression
analyses.
Association between NT-proBNP and NRG1-β concentra-
tions in HFpEF and HFrEF were tested with ischaemia de-
fined as the presence of macrovascular CAD as an
interaction term.
Associations with outcome were determined with Kaplan–
Meier and Cox proportional hazards models with ischaemia
as an interaction term. In the final multivariable Cox regres-
sion model, four clinically significant covariates, age, sex, esti-
mated glomerular filtration rate, and NT-proBNP, were
included. Due to non-normal distribution plasma and serum,
biomarkers were analysed in log-transformed format. P-
values were two-sided, and statistical significance was set at
0.05. Statistical analyses were performed using SAS software
version 9.3 (SAS Institute, Cary N. C, USA).
Ethics
The KaRen and MetAnEnd studies were conducted according
to International Conference on Harmonization and Good Clin-
ical Practice guidelines. The investigation conforms with the
Declaration of Helsinki and was approved by the ethical re-
view board at Karolinska Institutet. Written informed
consent was obtained from all participants prior to study
participation.
Results
Patients
Clinical characteristics of HFpEF, HFrEF, patients receiving
LVAD or HTx, and healthy controls are presented in Table
1. Patients with HFpEF were median 73 (interquartile range
67;79) years old and 51% were women. NT-proBNP was
1000 [469;2330] ng/L, LVEF was 64% [58;68], E/e′ ratio
was 10.8 [8.3;14.0], and LAVI 43.3 mL/m2 [37.2;53.8]. A
proportion of 23% had increased filling pressures E/e′
>15; 67% had e′ <9; 89% had enlarged left atria, LAVI
>34 mL/m2; and 61% fulfilled criteria for left ventricular
hypertrophy. The median age of patients with HFrEF was
63 [52;68] years, and 19% were female. NT-proBNP concen-
tration was 3290 ([1430;5860] ng/L and LVEF 21 [15;28] %;
both P-values versus HFpEF <0.001). Macrovascular CAD
was present in HFpEF and HFrEF in 29 [34%] vs. 38
(44%), respectively (ns).
Neuregulin1-β concentrations
As depicted in Figure 1 NRG1-β was higher in HFpEF, (6.5 [2.1-
11.3]ng/mL compared to HFrEF 3.6 [2.1-7.6]ng/mL (P =
0.035). Concentrations decreased after LVAD treatment, 1.7
[0.9-3.6]ng/mL and HTx 2.1 [1.4-3.6]ng/mL (overall P <
0.001). NRG1-β was substantially lower in all groups, individ-
ually and overall, compared to controls: 29.0 ng/mL [23.1-
34.3] (P = 0.001).
Neuregulin1-β did not correlate with age, sex, co-
morbidities, and echocardiographic measures in
either HFpEF or HFrEF (Table 2). Among biomarkers in
HFpEF, only haemoglobin correlated with NRG1-β (β =
0.25; P = 0.029), and in HFrEF, ST2 (β = 0.43; P < 0.001),
adiponectin (β = 0.33; P = 0.004), and IGFBP1 (β = 0.37;
P = 0.001).
In HFpEF, NRG1-β decreased with increasing NYHA class
(overall P = 0.013) in contrast to HFrEF where NRG1-β was
higher in NYHA class IV versus III (P-value = 0.030). NRG1-β
stratified by NYHA class between HFpEF and HFrEF displayed
no significant difference.
In ischaemic HFpEF, NRG1-β was insignificantly lower (5.2
[1.5–8.9] ng/mL) compared with non-ischaemic HFpEF (7.0
[2.3–11.9] ng/mL; P = 0.274), whereas there was no differ-
ence in ischaemic HFrEF (3.3 [2.1–6.3]) and non-ischaemic
HFrEF (3.9 [2.1–7.7]); P = 0.484). Interestingly, stratifying
the HFpEF group by ischaemia, there was a trending
association between increasing NRG1-β and NT-proBNP
in ischaemic but not in non-ischaemic HFpEF (Figure 2A; P-
interaction = 0.589). This pattern was not seen in HFrEF (Fig-
ure 2B).
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Association with outcome
Median follow-up time in patients with HFpEF and in patients
with HFrEF was 522 days [238;1089] and 204 days [56;415],
respectively. No patient was lost to follow-up. In HFpEF, the
composite endpoint of all-cause death and HF hospitalization
occurred in 36 patients, whereof six were deaths. In HFrEF,
the composite endpoint of all-cause death, LVAD implanta-
tion, or HTx occurred in 56 patients out of which 28 were
deaths.
In HFpEF, concentration of NRG1-β was not associated
with the composite endpoint (hazard ratio (HR) per log in-
crease 0.75 [95% confidence interval (CI) 0.55–1.04; P-value
= 0.083]; Figure 3A). When stratified by ischaemia, there
was an association with outcome (log-rank P = 0.020), reveal-
ing that ischaemic HFpEF patients with NRG1-β above median
had a worse outcome (Figure 3C). The pattern was confirmed
in the multivariable model but did not reach statistical signif-
icance; ischaemic HFpEF (HR 1.07, 95% CI 0.52–2.17, P =
0.862) and non-ischaemic HFpEF (HR 0.71, 95% CI 0.48–
1.05, P = 0.085; Pinteraction = 0.553).
In HFrEF, NRG1-β was prognostic (Figure 3B) also in the
multivariable model (HR 1.45 [95% CI 1.04–2.03; P-value =
0.029]). The association with outcome persisted when strati-
fied for ischaemia (log-rank P = 0.003; Figure 3D) After adjust-
ments in the multivariable model; in ischaemic HFrEF (HR
1.17, 95% CI 0.68–2.04, P = 0.569) and in non-ischaemic
HFrEF (HR 1.48, 95% CI 0.93–2.36, P = 0.098).
In addition, we analysed outcome stratified by above or
below median NRG1-β and NT-proBNP. In HFpEF, worst out-
come was in patients below median NRG1-β and above NT-
proBNP (P = 0.049), while in patients with HFrEF, the strata
above median NRG1-β and above median NT-proBNP had
the poorest prognosis (P < 0.001; Supporting Information,
Figure S1).
Discussion
Neuregulin1-β was reduced in both HFpEF and, even more, in
HFrEF compared with healthy controls. In HFrEF, concentra-
tions were further decreased after LVAD and HTx. In HFrEF
and ischaemic HFpEF, higher levels of NRG1-β were associ-
ated with worse outcomes. In contrast, in non-ischaemic
HFpEF, it was reversed, and NRG1-β appeared to be poten-
tially protective with higher concentrations tending to be as-
sociated with better outcomes. The opposing relationship of
NRG1-β with outcomes raises the possibility of a compensa-
tory increase of cardioprotective NRG1-β from the endothe-
lial microvasculature exposed to oxidative stress in non-
ischaemic HFpEF, but this compensatory effect is
overwhelmed in the presence of ischaemia in HFrEF and isch-
aemic HFpEF.
Neuregulin1-β concentrations
We confirm previous findings in HFrEF demonstrating an as-
sociation between higher concentrations of circulating
NRG1-β and HF disease severity.8,9 In addition, we demon-
strate lower concentrations after LVAD and HTx. NRG1, like
BNP, has been reported to be cardioprotective and part of
the adaptive physiologic response in HF, that is, NRG1, like
BNP, is a risk marker for more severe HFrEF and worse out-
comes but not a risk factor that causes worse outcomes.10
The most elevated concentrations of NRG1-β were found in
healthy controls. This may be explained by a slightly lower
age and absence of inflammation, contributing to a more pre-
served endothelial function.
We found lower concentrations of circulating NRG1-β in
HFrEF compared with HFpEF and controls which is counterin-
tuitive as the neurohormonal activation is greater in HFrEF.
Our patients with HFrEF all had severe HF referred for ad-
vanced interventions such as LVAD or HTx reflecting signifi-
cant pump failure in later stages of HF. Animal models
suggest that concentric left ventricular hypertrophy and me-
chanical wall strain initially increase NRG1 mRNA expres-
sion.11 At the same time, the ERBB2 and ERBB4 receptors
are downregulated.7 As terminal HF approaches and pump
failure occurs, NRG1 declines potentially due to increasing cir-
culating levels of angiotensin II and epinephrine.11 Although
speculative, the lower NRG1-β concentrations in our patients
with HFrEF after intervention could be mediated by a declin-
ing neurohormonal activation accompanied by upregulation
of the ERBB2 and ERBB4 receptors.7,12
Figure 1 Concentrations of log NRG1-β in HFpEF, HFrEF, 1 year after left
ventricular assist device implantation (LVAD), 1 year after heart trans-
plantation (HTx), and healthy controls. All groups individually and overall
versus control P < 0.001.
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Table 2 Correlates of NRG1-β in the 86 patients with HFpEF and the 86 patients with HFrEF from regression analyses.
Variable
HFpEF HFrEF
β-coefficient P-value β-coefficient P-value
Patient history
Age; median (Q1;Q3) 0.007 0.950 0.05 0.659
Gender (men/women) 1.00 0.65–1.54 0.987 1.02 0.54–1.93 0.956
Medical history
COPD 0.73 0.45–1.20 0.219 0.87 0.41–1.84 0.720
T2DM 0.78 0.50–1.21 0.269 0.76 0.45–1.29 0.302
Cancer 0.72 0.43–1.19 0.200 0.77 0.33–1.77 0.533
Hypertension 1.24 0.74–2.08 0.401 — —
Atrial fibrillation/flutter 1.36 0.87–2.11 0.174 1.04 0.65–1.68 0.870
Coronary artery disease (in ref ischaemic aetiology) 0.72 0.46–1.12 0.140 0.76 0.46–1.24 0.265
Measurements
Weight (kg) 0.10 0.388 0.03 0.742
BMI (kg/m2) 0.12 0.304 0.03 0.815
Systolic blood pressure (mmHg) 0.01 0.919 0.06 0.627
Diastolic blood pressure (mmHg) 0.02 0.855 0.09 0.455
Heart rate (b.p.m.) 0.15 0.191 0.07 0.548
Treatment
ARB 0.69 0.44–1.08 0.104 31 (36)
ACE inhibitor 1.26 0.81–1.95 0.309 51 59
Beta-blocker 1.05 0.62–1.79 0.844 85 (99)
Thiazide diuretics
Potassium sparing diuretics 0.94 0.56–1.58 0.808 58 (67)
Loop diuretics 1.11 0.70–1.76 0.652 75 (87)
Calcium channel blocker 1.06 0.67–1.69 0.805 4 (5)
Anticoagulants 1.08 0.70–1.67 0.717 53 (62)
Antiplatelet 1.00 0.63–1.56 0.961 22 (26)
Statins 0.71 0.46–1.12 0.140 38 (44)
ECHO parameters
LVEF (%) 0.08 0.509 0.04 0.733
LVEDd (mm) 0.05 0.717 0.02 0.894
LAVI (mL/m2) 0.03 0.896
Left ventricular mass index (g/m2)
Men 0.11 0.575
Women 0.28 0.324
E/e′ ratio 0.11 0.418
Biochemistry
NT-proBNP (ng/L) 0.07 0.545 0.09 0.434
MR-proANP 0.07 0.569 0.20 0.171
MR-proADM 0.02 0.868 0.29 0.051
Hb (g/dL) 0.25 0.029 0.04 0.757
Creatinine (μmol/L) 0.02 0.867 0.08 0.460
eGFR (MDRD) (mL/min/1.73 m2) 0.02 0.887 0.09 0.442
Copeptin 0.05 0.685 0.15 0.324
Sodium 0.12 0.318 0.23 0.039
Potassium 0.03 0.818 0.024 0.833
Glucose fasting (mmol/L) 0.19 0.106 0.12 0.344
Insulin (μU/mL) 0.14 0.248 0.06 0.646
HOMA-IR 0.19 0.103 0.08 0.541
Adiponectine (mg/L) 0.13 0.265 0.33 0.004
Leptin (ng/L) 0.10 0.395 0.04 0.741
IGF1 (mikrog/L) 0.09 0.446 0.07 0.543
SD score IGF1 0.05 0.677 0.08 0.642
IGFBP1 (mikrog/L) 0.04 0.729 0.37 0.001
IGFBP7 (μg/L) 0.06 0.608 0.31 0.008
sST2 (g/L) 0.13 0.277 0.43 <0.0001
Galectin-3 (g/L) 0.04 0.752 0.17 0.139
ACE, angiotensin converting enzyme; ARB, angiotensin II receptor blocker; BMI, body mass index; COPD, chronic obstructive pulmonary
disease; eGFR, estimated glomerular filtration rate; Hb, haemoglobin; HFpEF, heart failure with preserved ejection fraction; HFrEF, heart
failure with reduced ejection fraction; HOMA-IR, homeostatic model assessment of insulin resistance; IGF1, insulin-like growth factor 1;
IVRT, isovolumic relaxation time; LAVI, left atrial volume index; LVEDd, left ventricular end diastolic diameter; LVEF, left ventricular ejection
fraction; MDRD, Modification of Diet in Renal Disease; MR-proADM, mid-regional pro-adrenomedullin; MR-proANP, mid-regional pro
atrial natriuretic peptide; NT-proBNP, N-terminal pro-brain natriuretic peptide; NRG1-β, neuregulin1-β; SD, standard deviation; T2DM,
type 2 diabetes mellitus.
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Prognostic implications of neuregulin1-β
In concordance with previous findings, we found higher
NRG1-β to be associated with increased mortality in HFrEF.8
In addition, Ky and colleagues suggest NRG1-β as a prognostic
predictor in ischaemic but not in non-ischaemic HFrEF. In our
study, it appeared prognostic in HFrEF regardless of the pres-
ence of ischaemia defined as ischaemic HF aetiology. We add
new information on the role of NRG1-β in ischaemic versus
non-ischaemic HFpEF. Patients with HFpEF with ischaemia de-
fined as the presence of CAD and a high NRG1-β had the
worst outcomes, whereas patients with HFpEF without CAD
and high NRG1-β had the best outcomes.
In support of the association between outcome and NRG1-
β in ischaemia, it has been shown that NRG/erbB signalling is
activated in the setting of ischaemia-reperfusion injury,13 and
Figure 3 (A–D) Kaplan–Meier analyses displaying increased survival free of HF hospitalization by median NRG1-β (A) in HFpEF displaying improved
prognosis above median NRG1-β; (B) in HFrEF displaying worse prognosis above median NRG1-β; (C) in HFpEF displaying worse prognosis in the pres-
ence of ischaemia above median NRG1-β but still improved prognosis in the absence of ischaemia; and (D) in HFrEF displaying worse prognosis above
median NRG1-β regardless of the presence of ischaemia.
Figure 2 Association between log NRG1-β concentrations and log NT-proBNP and interaction of ischaemia (A) in HFpEF and (B) in HFrEF. Curves depict,
with 95% confidence interval, presence of ischaemia in red and no ischaemia present in blue.
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NRG1-β concentrations are initially elevated in patients with
stress-induced ischaemia, but as HFrEF progresses, the endo-
thelium is unable to release NRG1-β and concentrations dete-
riorate. Both NRG1-β mRNA expression and ERBB2 and
ERBB4 receptors are downregulated in hypoxic versus
normoxic areas,14 and NRG1 is inversely correlated with an-
giographic severity.15
This raises the possibility, which needs further studies and
confirmation, that NRG1-β has diverging roles in the presence
and evolvement of ischaemia in HFpEF. In non-ischaemia, de-
clining NRG1-β concentrations may rather reflect the disease-
driving oxidative stress contributing to the microvascular en-
dothelial dysfunction that is hypothesized to drive the HFpEF
syndrome.3
Endothelial dysfunction, highly prevalent in HF regardless
of LVEF, is associated with cardiovascular death and HF hospi-
talization. In the myocardium, NRG1 is primarily produced by
the microvascular endothelium in response to mechanical
stretch, oxidative stress, and hypoxia.5 NRG1/ErbB signalling
and NRG1 are suggested to increase the number of
microvessels in post-ischaemic animal models.16 Further,
demonstrating the link between endothelial dysfunction and
oxidative stress, we found that NRG1-β correlated with the
oxidative stress marker IGFBP-1 in our patients with HFrEF.
Even if coronary microvascular inflammation and dysfunc-
tion occur in both HFrEF and HFpEF, it is suggested to have
a more prominent role in the pathophysiology and disease
development in HFpEF.3 Supporting this hypothesis, we re-
cently showed that coronary microvascular dysfunction as de-
fined by reduced coronary flow reserve was present in 75% of
patients with HFpEF and also correlated with peripheral en-
dothelial dysfunction.17
Neuregulin1 is interesting in this aspect. It may act on both
the ventricular and cardiomyocyte levels attenuating endo-
thelial dysfunction and collagen synthesis thus potentially im-
proving passive ventricular stiffness.18–20 NRG1 has an impact
on endothelial dysfunction reducing pro-inflammatory cyto-
kines affecting the pro-fibrotic transforming growth factor
beta 1 signalling pathway through ErbB4 receptor activa-
tion.19 It also acts on the cardiomyocyte calcium metabolism,
at the level of the sarcoplasmatic reticulum through phos-
phorylation of phospholamban and correct the altered titin
phosphorylation.21,22
Limitations
There are limitations in this relatively small single centre co-
hort study. Measured plasma NRG1-β reflects the circulation
of NRG1 but not necessarily biologically active peptide or re-
ceptor activation. The definition of the composite outcome
differed between the groups. In HFrEF, a surrogate endpoint
reflecting clinical deterioration, that is, HTx or LVAD, was in-
cluded because these events reduce competing risk. In
HFpEF, HF hospitalization was a part of the composite end-
point. We selected these most clinically relevant composite
outcomes because we did not compare outcomes in HFrEF
versus HFpEF, but we compared associations between
NRG1-β and outcomes in HFrEF versus in HFpEF separately.
The small sample size may hamper the results and does not
allow extensively adjusted survival analyses, but we have ad-
justed for a few important variables such as renal function,
NT-proBNP, age, and sex. Further, we have measured circu-
lating NRG1-β that does not necessarily reflect processes in
the myocardium.
Conclusions
Neuregulin1-β was reduced in both HFpEF and, even more, in
HFrEF compared with healthy controls. In HFrEF, concentra-
tions were further decreased after LVAD and HTx. In HFrEF
and ischaemic HFpEF, higher levels of NRG1-β were associ-
ated with worse outcomes. In contrast, in non-ischaemic
HFpEF, it was reversed, and NRG1-β appeared to be poten-
tially protective with higher concentrations tending to be as-
sociated with better outcomes. The opposing relationship of
NRG1-β with outcomes raises the possibility of compensatory
increases of cardioprotective NRG1-β from the endothelial
microvasculature exposed to oxidative stress in non-
ischaemic HFpEF, but this compensatory effect is
overwhelmed in the presence of HFrEF and ischaemic HFpEF.
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